Cellectis S.A. - American Depositary Shares (CLLS)

Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session.

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.